EDESA BIOTECH INC (EDSA) Stock Price, Quote, News and Overview
NASDAQ:EDSA - Nasdaq - CA27966L3065 - Common Stock - Currency: USD
EDSA Quote, Performance and Key Statistics
EDESA BIOTECH INC
NASDAQ:EDSA (2/18/2025, 4:23:47 PM)
After market: 2.55 +0.05 (+2%)2.5
-0.19 (-7.06%)
The current stock price of EDSA is 2.5 USD. In the past month the price increased by 59.17%. In the past year, price decreased by -49.91%.
EDSA Latest News, Press Relases and Analysis
Wondering what's happening in today's pre-market session?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing...
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund...
Edesa Biotech Reports Fiscal Year 2024 Results
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing...
EDSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.39 | 346.80B | ||
| AMGN | AMGEN INC | 14.77 | 157.23B | ||
| GILD | GILEAD SCIENCES INC | 22.83 | 131.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1593.48 | 118.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.9 | 74.34B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.24B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.41B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.29 | 19.90B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About EDSA
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. The company is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. The company has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The company is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.
Company Info
EDESA BIOTECH INC
100 Spy Crt
Markham ONTARIO L3R 5H6 CA
CEO: Pardeep Nijhawan
Employees: 16
Company Website: https://www.edesabiotech.com/
Investor Relations: http://ir.stellarbiotechnologies.com/
Phone: 19054751234
EDSA FAQ
What is the stock price of EDSA?
The current stock price of EDSA is 2.5 USD.
What is the symbol for EDESA BIOTECH INC stock?
The exchange symbol of EDESA BIOTECH INC is EDSA and it is listed on the Nasdaq exchange.
On which exchange is EDSA stock listed?
EDSA stock is listed on the Nasdaq exchange.
Is EDSA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EDSA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EDSA.
Does EDSA stock pay dividends?
EDSA does not pay a dividend.
When does EDSA stock report earnings?
EDSA will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of EDSA?
EDSA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
What is the Short Interest ratio of EDSA stock?
The outstanding short interest for EDSA is 0.72% of its float.
EDSA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to EDSA. When comparing the yearly performance of all stocks, EDSA is a bad performer in the overall market: 80.4% of all stocks are doing better.
EDSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDSA. EDSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EDSA Financial Highlights
Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS increased by 36.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.77% | ||
| ROE | -311.44% | ||
| Debt/Equity | 0 |
EDSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EDSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.